Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Amagen
Thousand Oaks, California, United States
- Ownership
- Private
- Employees
- ~25200
- Development stage
- Other
01
Overview
Amgen has more than 70 commercialized drugs, 17 clinical programs in Phase III, 8 in Phase II, and 19 in Phase I. Major commercial drugs include denosumab, etanercept, evolocumab, apremilast, teprotumumab, romosozumab, carfilzomib, romiplostim, and darbepoetin alfa. The company’s newest entrant, MariTide (anti-obesity), is in advanced clinical studies. Amgen's portfolio demonstrates efficacy and regulatory approval in multiple therapeutic areas including oncology, cardiology, bone health, immunology, and rare diseases.
- Therapeutic areas
- ImmunologyEndocrinologyRheumatologyHematologyDermatologyCardiovascularOncology
- Modalities
- Monoclonal antibodyAntibody-drug conjugateSmall moleculeBiologicPeptidesProteinRNA therapyGene therapy
- Industry
- Pharma
02
Partnerships
Harvard UniversityKhan AcademyCDC FoundationAssociation of Black Cardiologists
Beyond the preview
Go deeper on Amagen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amagen.